Clinical Trial

Home-Based tDCS Treatment Of Major Depressive Disorder

Study acronym: REACH-tDCS
Recruiting
View on ClinicalTrials.gov →
Summary
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-15; most recent amendment 2026-03-20.
Trial Details
NCT Number NCT06976697
Lead Sponsor Sooma Medical Inc
Conditions Major Depressive Disorder (MDD)
Enrollment 200 participants
Start Date 2025-06-27
Primary Completion 2026-10-10 (estimated)
Study Completion 2026-12-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-14